- Home
- RCKY vs CRDF Comparison
RCKY vs CRDF Comparison
Compare RCKY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- CRDF
- Stock Information
- Founded
- RCKY 1932
- CRDF 1999
- Country
- RCKY United States
- CRDF United States
- Employees
- RCKY N/A
- CRDF N/A
- Industry
- RCKY Shoe Manufacturing
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCKY Consumer Discretionary
- CRDF Health Care
- Exchange
- RCKY Nasdaq
- CRDF Nasdaq
- Market Cap
- RCKY 196.3M
- CRDF 233.5M
- IPO Year
- RCKY 1993
- CRDF N/A
- Fundamental
- Price
- RCKY $30.27
- CRDF $2.18
- Analyst Decision
- RCKY Buy
- CRDF Strong Buy
- Analyst Count
- RCKY 1
- CRDF 6
- Target Price
- RCKY $40.00
- CRDF $10.58
- AVG Volume (30 Days)
- RCKY 81.7K
- CRDF 2.4M
- Earning Date
- RCKY 07-29-2025
- CRDF 07-29-2025
- Dividend Yield
- RCKY 2.07%
- CRDF N/A
- EPS Growth
- RCKY 24.23
- CRDF N/A
- EPS
- RCKY 2.48
- CRDF N/A
- Revenue
- RCKY $462,328,000.00
- CRDF $545,000.00
- Revenue This Year
- RCKY $7.02
- CRDF N/A
- Revenue Next Year
- RCKY $3.96
- CRDF N/A
- P/E Ratio
- RCKY $12.08
- CRDF N/A
- Revenue Growth
- RCKY N/A
- CRDF N/A
- 52 Week Low
- RCKY $11.93
- CRDF $2.09
- 52 Week High
- RCKY $33.04
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- RCKY 70.80
- CRDF 32.16
- Support Level
- RCKY $25.76
- CRDF $2.17
- Resistance Level
- RCKY $31.30
- CRDF $2.39
- Average True Range (ATR)
- RCKY 1.08
- CRDF 0.11
- MACD
- RCKY 0.26
- CRDF 0.02
- Stochastic Oscillator
- RCKY 84.75
- CRDF 12.77
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.